Business Wire

Fluence Supporting Premium Dutch Floriculture Brands to Future-Proof and Increase Sustainability

9.2.2023 16:30:00 EET | Business Wire | Press release

Share

Fluence, a leading global provider of energy-efficient LED lighting solutions for floriculture, medicinal cannabis and food production, is supporting sustainability and operational cost efficiency amid volatile energy market conditions in Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230209005211/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Orchids under Fluence LED lighting at Bernhard Kwekerijen, a rose, orchid and patio plant nursery. (Photo: Business Wire)

Europe’s soaring energy prices have affected many growers in countries like the Netherlands that primarily produce electricity via the gas-powered cogeneration method. Gas prices have historically balanced between €15 and €20 per megawatt-hour (MWh) but peaked at over €300 per MWh in 2022 because of volatility due to supply, storage and weather conditions. Current energy prices have dropped to €60 per MWh, remaining roughly three times higher than what many growers planned to pay for electricity.

Leading floriculture companies dedicated to delivering high-quality products to customers—including Bernhard Kwekerijen, Moerman Lilium, Deliflor Chrysanten, Beyond Chrysant and Ten Have Plant—have made the switch from high-pressure sodium (HPS) fixtures to Fluence's LED technology, which increase photon output and energy efficiency.

“As they confront the unpredictability of Europe’s energy market, Dutch cultivators are increasingly focused on future-proofing their cultivation strategies by decreasing their dependency on fossil energy and engaging in sustainable practices,” said Gert-Jan Goes, horticulture specialist at Fluence. “Fluence’s RAPTR light fixture and Wireless Flex Dimming control panel help growers maximize their return on investment while increasing control over light intensity while increasing control over light intensity and dimming up and down creates maximum flexibility to profit from highly fluctuating energy markets.”

Moerman Lilium, a lily cultivator, has 13 hectares of crops under full LED lighting and uses Fluence’s RAPTR fixtures regulated via a Wireless Flex Dimming controller. The company—which monitors European energy prices very closely—uses Fluence solutions to react quickly and modify light intensity based on market conditions. Moerman Lilium expects to save at least 45% on electricity costs with the investment in Fluence’s LED lighting solutions.

“LED lighting allows us to be more energy efficient while adjusting our electricity use based on fluctuations in energy prices,” said Jan Moerman, co-owner of Moerman Lilium. “Switching to Fluence LEDs has saved us money and given us more flexibility in a constantly changing energy market.”

Deliflor Chrysanten is the global market leader in breeding and propagating chrysanthemum varieties. The company was in search of a high-efficiency lighting solution featuring additional green light in the spectrum for better visibility and growth. Deliflor Chrysanten opted for Fluence’s RAPTR Broad R8 spectrum in their recently renewed breeding facilities to guarantee the best circumstances for their newest varieties. The first flower trial grown under the Fluence’s fixtures turned out very successful last January. Beyond Chrysant, a leading Dutch chrysanthemum cultivator, also chose Fluence’s RAPTR solution for its customizability and high-visibility spectrum that create increased efficiency in its integrated crop management practices. Installing Fluence’s LED technology has allowed Beyond Chrysant to gain greater control over the oscillating European energy market. The company was recently named a finalist for Stichting Tuinbouw Ondernemersprijs’ “2023 Horticultural Entrepreneur Award.”

Even in hybrid lighting environments, growers are seeing the benefits of using LED technology. Bernhard Kwekerijen—a rose, orchid and patio plant nursery—promotes a carbon-neutral and sustainable operation by using geothermal heat and its own photovoltaic field of solar panels to generate energy. By incorporating Fluence’s RAPTR fixtures alongside legacy HPS solutions and maximizing light control with Wireless Flex Dimming, Bernhard Kwekerijen has elevated CO2-neutral cropping in its Phalaenopsis cultivation.

“Fluence’s technology stands out because it affords the greatest flexibility in modifying energy consumption and light intensity according to energy market price instability,” said Dennis Raadschelders, strategic account manager for commercial agriculture at Fluence. “Our Dutch floriculture growers have harnessed control over operational expenses without sacrificing product quality by emitting more light when energy prices are low, and quickly reducing light when energy prices rise.”

Fluence’s team of horticultural experts work closely alongside partners to design lighting programs based on operations-specific crop and sustainability goals. Ten Have Plant, one of the oldest potted plant nurseries in Westland, selected Fluence as its lighting solutions partner to achieve better crop and root development in addition to reducing costs and increasing energy efficiency. Ten Have Plant worked with Fluence’s horticulture team to design a lighting plan to produce cyclamen for half the year and campanula in the other half, selecting VYPR 3p Broad R6 top lights to gain control over seasonal light conditions and electricity consumption year-round.

“Fluence LED fixtures are widely used by leading cannabis, commercial agriculture and floriculture companies across Europe, demonstrating the flexibility and universal benefit in transitioning to LED technology,” said David Cohen, CEO of Fluence. “We are excited to work with Dutch floriculture growers who have deep roots in the industry and support their management of environmental conditions, sustainable operations and the highest quality crops.”

For more information on Fluence, visit www.fluence.science.

About Fluence

Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 160 93335045

For North America,
Callie Neatherlin
callie@redfancommunications.com
512-439-9720

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 08:45:00 EEST | Press release

Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In

Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release

Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye